Literature DB >> 10627465

Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

D T Eitzman1, R J Westrick, E G Nabel, D Ginsburg.   

Abstract

Occlusive thrombosis depends on the net balance between platelets, coagulation, and fibrinolytic factors. Epidemiologic information suggests that plasminogen activator inhibitor-1 (PAI-1), a central regulator of the fibrinolytic system, plays an important role in determining the overall risk for clinically significant vascular thrombosis. Vitronectin (VN), an abundant plasma and matrix glycoprotein, binds PAI-1 and stabilizes its active conformation. This study assessed the role of PAI-1 and VN expression in the formation of occlusive vascular thrombosis following arterial or venous injury. The common carotid arteries of 17 wild-type (WT) mice and 8 mice deficient in PAI-1 were injured photochemically while blood flow was continuously monitored. WT mice developed occlusive thrombi at 52.0 +/- 3.8 minutes (mean +/- SEM) following injury; mice deficient in PAI-1 developed occlusive thrombosis at 127 +/- 15 minutes (P <.0001). Mice deficient in VN (n = 12) developed vascular occlusion 77 +/- 11 minutes after injury, intermediate between the values observed for WT mice (P <.03) and mice deficient in PAI-1 (P <.01). PAI-1 and VN also affected the time to occlusion after injury to the jugular vein. Three WT mice developed occlusive venous thrombosis an average of 39.7 +/- 1 minutes following the onset of injury, whereas the jugular veins of 4 mice deficient in PAI-1 and 4 deficient in VN occluded 56.7 +/- 5 and 58.7 +/- 2 minutes, respectively, following injury (P <.04 and P <.01 compared to WT mice). These results suggest that endogenous fibrinolysis and its regulation by PAI-1 and VN have important roles in the development of occlusive vascular thrombosis after vascular injury. (Blood. 2000;95:577-580)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

3.  Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.

Authors:  Feng Xu; Judianne Davis; Jianting Miao; Mary Lou Previti; Galina Romanov; Kelly Ziegler; William E Van Nostrand
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

4.  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Authors:  Li He; Cristina P Vicente; Randal J Westrick; Daniel T Eitzman; Douglas M Tollefsen
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

5.  Vitronectin from brain pericytes promotes adult forebrain neurogenesis by stimulating CNTF.

Authors:  Cuihong Jia; Matthew P Keasey; Hannah M Malone; Chiharu Lovins; Richard R Sante; Vlad Razskazovskiy; Theo Hagg
Journal:  Exp Neurol       Date:  2018-11-06       Impact factor: 5.330

6.  Mutation of the Kunitz-type proteinase inhibitor domain in the amyloid β-protein precursor abolishes its anti-thrombotic properties in vivo.

Authors:  Feng Xu; Judianne Davis; Michael Hoos; William E Van Nostrand
Journal:  Thromb Res       Date:  2017-05-04       Impact factor: 3.944

Review 7.  Animal models of venous thrombosis.

Authors:  Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

8.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

9.  Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease.

Authors:  Hakan Ekmekci; Huseyin Sonmez; Ozlem B Ekmekci; Zeynep Ozturk; Nergiz Domanic; Emine Kokoglu
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

10.  How to analyze the anticoagulant and antithrombotic mechanisms of action in fucanome and galactanome?

Authors:  Vitor H Pomin
Journal:  Glycoconj J       Date:  2014-02       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.